Superworth

Fate Therapeutics price to sales ratio FATE

Market value divided by revenue over the last twelve months, since 2019.

Today, Nov 2, 2026
37.1×
7-year median
29.2×
Against its 7-year history
58th
percentile: 0 is its lowest day, 100 its highest
7-year range
1.4× to 198×
Peer median
2.6×

Fate Therapeutics' price to sales ratio is 37.1× as of Nov 2, 2026.

That is above its 7-year median of 29.2×, close to the middle of its last 7 years.

Over that time it ranged from 1.4× in Oct 2023 to 198× in Jun 2021.

The median for 3 biotech stocks of a similar size is 2.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far37.1×15.9×57.2×
202516.2×6.3×22.5×
202413.6×3.5×95.6×
20233.5×1.4×9.7×
202214.2×14.2×84.4×
2021102×83.8×198×
2020189×147×194×
2019156×108×198×

Against its peers

Companies in Biotechnology nearest Fate Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
FATEFate Therapeutics37.1×
PLXProtalix BioTherapeutics2.6×
MGTXMeiraGTx2.3×
VCELVericel6.8×
Peer median2.6×

Where Fate Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Fate Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.